No definition available.
Malignant neoplasm of ureter, excluding all cancers (controls excluding all cancers)
C3_URETER_EXALLC
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
269 |
4. Check minimum number of eventsNone |
269 |
5. Include endpointsNone |
269 |
6. Filter based on genotype QC (FinnGen only) |
269 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE_EXALLC
Extra metadata
- First used in FinnGen datafreeze
- DF12
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of ureter, excluding all cancers (controls excluding all cancers)
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of urinary organs, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm, wide definition for exclusion
- Malignant neoplasm, wide definition for exclusion, excluding all cancers (controls excluding all cancers)
- Any operation in hilmo
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded (different definition than used in FinnGen).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 269 | 77 | 192 |
| Unadjusted period prevalence (%) | 0.07 | 0.03 | 0.08 |
| Median age at first event (years) | 72.53 | 72.29 | 72.63 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 74
- Matched controls
- 740
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C66
ICD-10 Finland
Malignant neoplasm of ureter
+∞
84.2
64
*
8120/3-C66.9
ICD-O-3
Transitional cell carcinoma, NOS, of ureter
+∞
80.6
62
*
UKC02
NOMESCO Finland
Cystoscopy
86.3
49.4
67
73
C67.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of bladder
+∞
37.8
33
*
N13.3
ICD-10 Finland
Other and unspecified hydronephrosis
193.7
34.0
33
*
UKB02
NOMESCO Finland
Retrograde ureteroscopy
276.6
33.8
32
*
R31
ICD-10 Finland
Unspecified haematuria
24.0
29.1
46
47
KAC20
NOMESCO Finland
Nephroureterectomy
+∞
27.9
25
*
D41.2
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Ureter
+∞
27.9
25
*
C67.9
ICD-10 Finland
Malignant neoplasm: Bladder, unspecified
+∞
26.7
24
*
KCD02
NOMESCO Finland
Transurethral resection of bladder
130.8
25.6
26
*
130
Kela drug reimbursment
Malignant tumour
+∞
23.1
21
*
KBV02
NOMESCO Finland
Cystoscopic insertion of stent into ureter
109.0
22.1
23
*
KCD05
NOMESCO Finland
Excision of bladder lesion during urinary tract endoscopy with photodynamic diagnosis (PDD)
+∞
20.8
19
*
KAC21
NOMESCO Finland
Percutaneous endoscopic nephroureterectomy
+∞
17.4
16
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
14.0
13
*
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
22.3
14.0
20
12
TPH07
NOMESCO Finland
Cathetrisation of artery
10.8
13.3
27
37
WX302
NOMESCO Finland
Thoracal epidural anesthesy
27.0
12.7
17
8
D41.4
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Bladder
56.6
12.4
14
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
10.9
12.1
24
31
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
14.7
12.0
20
18
H02AB02
ATC
dexamethasone; systemic
141.1
11.8
12
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
11.8
11
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
11.8
11
*
UKC05
NOMESCO Finland
Cystoscopy and bladder biopsy
127.3
10.7
11
*
C65
ICD-10 Finland
Malignant neoplasm of renal pelvis
+∞
10.7
10
*
A04AA02
ATC
granisetron; systemic, transdermal
+∞
10.7
10
*
JN4BD
NOMESCO Finland
Extensive body CT
12.8
10.2
18
18
B01AB10
ATC
tinzaparin; parenteral
25.8
9.7
13
6
KH1BT
NOMESCO Finland
Urinary tract cathetrisation with X-ray guidance
114.0
9.7
10
*
C67.2
ICD-10 Finland
Malignant neoplasm: Lateral wall of bladder
+∞
9.6
9
*
JN4AD
NOMESCO Finland
Body CT examination
15.3
9.4
15
12
Z51.5
ICD-10 Finland
Palliative care
22.1
9.3
13
7
KBV12
NOMESCO Finland
Transluminal endoscopic removal of stent from ureter
42.4
9.3
11
*
XF603
NOMESCO Finland
Direct intraarterial blood pressure measurement
19.3
8.9
13
8
KH1AD
NOMESCO Finland
CT of urinary organs
23.4
8.8
12
6
A04AA01
ATC
ondansetron; systemic, rectal
31.8
8.8
11
*
WX402
NOMESCO Finland
General anaesthesia
7.5
8.7
21
37
UKA02
NOMESCO Finland
Retrograde ureteronephroscopy
+∞
8.5
8
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
8.5
8
*
KBD00
NOMESCO Finland
Partial excision of ureter
+∞
8.5
8
*
JN4CD
NOMESCO Finland
Very extensive body CT
38.0
8.3
10
*
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
6.3
8.3
23
49
WX408
NOMESCO Finland
General anesthesy, balanced
4.7
7.9
31
98
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
4.5
7.6
31
101
KCD32
NOMESCO Finland
Cystoscopic destruction of tumour of bladder
88.6
7.6
8
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
7.4
7
*
KC1GB
NOMESCO Finland
Cystography with X-ray
+∞
7.4
7
*
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
6.0
7.4
21
46
B01AB05
ATC
enoxaparin; parenteral
4.1
7.3
36
139
WZC30
NOMESCO Finland
Teaching
7.0
7.0
17
30
KBH20
NOMESCO Finland
Replantation of ureter
76.1
6.5
7
*
A03FA01
ATC
metoclopramide; systemic, rectal
5.6
6.5
19
43
XX3DW
NOMESCO Finland
Time consuming IT work
10.0
6.3
12
14
N13.1
ICD-10 Finland
Hydronephrosis with ureteral stricture, not elsewhere classified
+∞
6.3
6
*
J01MA12
ATC
levofloxacin; systemic
4.4
6.1
23
68
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
189
788
5.70
41.13
9.9
3.2
—
—
—
0
0
167
669
4.95
37.09
10.3
3.1
239.5
173.8
e6/l
0.18
147
515
145
605
4.03
28.48
10.4
3.0
0.4
0.4
e6/l
0.14
125
443
177
867
4.05
27.03
6.7
3.7
—
—
—
0
0
70
192
4.58
24.08
8.7
7.0
12.1
11.3
mmol/l
0.33
62
182
222
1340
4.76
23.63
14.2
4.5
4.8
2969.4
e6/l
—
5
33
109
424
3.64
22.78
3.3
2.1
—
—
—
0
0
49
117
4.90
19.79
4.0
1.4
58.9
5.4
ug/l
0.75
42
96
94
364
3.43
19.32
9.5
3.0
1.1
1.8
e6/l
0.60
71
202
176
991
3.24
18.97
10.1
3.9
9.4
12.5
umol/l
9.12
171
925
184
1076
3.25
18.32
9.5
5.7
1.2
1.2
mmol/l
0.75
151
912
165
922
3.04
17.53
7.2
3.7
32.5
34.9
g/l
6.10
154
855
93
391
3.11
16.29
9.2
2.7
1.7
1.0
e6/l
1.12
68
226
174
1058
2.83
14.83
13.7
5.8
4.6
4.5
e9/l
0.16
148
910
163
980
2.68
13.85
9.3
5.2
1.2
1.2
mmol/l
0.84
147
859
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
32
77
4.58
12.64
4.3
2.6
0.5
0.4
u/ml
0.50
15
37
59
223
3.11
12.08
4.6
3.0
237.5
243.7
u/l
0.21
54
209
187
1289
2.48
10.65
8.2
4.4
6.9
6.9
mmol/l
0.12
182
1207
206
1532
2.47
9.17
12.4
5.3
85.8
78.3
u/l
1.94
199
1390
64
294
2.54
8.89
8.2
6.3
-1.1
1.6
mmol/l
4.40
46
227
74
367
2.40
8.70
2.5
1.8
29.8
29.8
s
0.05
74
351
150
1000
2.13
8.43
8.0
5.4
0.0
0.0
estimate
0.00
39
165
113
684
2.12
8.11
5.0
2.1
2.3
2.3
mmol/l
0.51
98
558
150
1017
2.07
7.87
6.1
3.9
0.0
0.0
estimate
0.00
40
163
147
1007
2.01
7.30
6.1
4.0
0.0
0.0
estimate
0.00
39
171
59
291
2.32
6.90
3.8
2.6
18.2
22.6
%
2.01
53
249
39
162
2.65
6.56
5.3
3.7
1.1
2.2
mmol/l
0.87
29
117
35
138
2.77
6.51
1.9
1.4
—
—
—
0
0
51
244
2.35
6.37
7.3
3.6
0.8
2.0
mmol/l
1.75
41
194
34
144
2.56
5.49
1.5
1.5
—
—
—
0
0
117
802
1.81
5.28
3.4
2.7
187.8
153.2
ug/l
0.69
107
731
230
1964
2.18
4.94
32.7
14.3
42.7
27.2
mg/l
6.67
217
1538
64
374
1.93
4.70
2.1
1.7
—
—
—
0
0
77
480
1.85
4.63
4.7
3.9
203.9
313.5
ng/l
0.25
66
415
44
227
2.12
4.54
7.0
3.3
—
—
—
0
0
71
434
1.86
4.53
4.1
2.2
2.5
2.4
mmol/l
3.07
58
364
85
553
1.79
4.42
2.4
2.6
382.5
9592.3
umol/l
2.97
66
462
89
587
1.77
4.42
2.4
2.2
2.8
3.1
mg/l
0.59
75
500
61
367
1.86
4.06
32.2
29.7
1.3
1.4
inr
0.29
14
45
22
88
2.63
3.99
2.4
1.4
—
—
—
0
0
215
1847
1.82
3.77
37.5
13.6
56.6
71.8
ml/min/173m2
17.97
193
1481
35
184
2.04
3.44
5.3
1.7
391.6
352.9
nmol/l
0.43
35
161
32
166
2.05
3.26
8.3
2.9
1.2
1.2
mmol/l
0.33
27
134
186
1565
1.61
3.21
43.8
17.3
14.5
13.8
%
7.73
179
1526
130
1013
1.55
3.11
2.4
2.1
86.1
91.8
pmol/l
0.78
77
521
21
97
2.26
2.85
2.7
1.5
—
—
—
0
0
43
259
1.79
2.83
1.8
1.7
—
—
—
0
0
5
6
8.46
2.76
2.0
1.0
—
—
—
0
0
14
54
2.68
2.75
1.3
1.4
—
—
—
0
0
106
808
1.51
2.72
2.3
2.3
81.3
77.9
nmol/l
0.53
93
683
42
256
1.76
2.66
1.8
1.8
—
—
—
0
0
177
1509
1.51
2.57
3.7
4.1
18.1
13.2
mm/h
2.97
163
1356
5
7
7.25
2.56
1.8
1.1
—
—
—
0
0
233
2127
1.71
2.37
41.5
18.1
139.1
139.7
mmol/l
3.32
227
2053
77
564
1.51
2.33
7.0
4.1
0.0
0.0
estimate
0.00
32
162
233
2131
1.70
2.30
42.4
18.2
4.1
4.0
mmol/l
4.40
227
2058
25
136
1.92
2.27
1.9
1.6
—
—
—
0
0
17
82
2.15
2.12
2.9
3.8
—
—
—
0
0
188
1657
1.45
2.04
38.4
16.2
36.9
39.1
%
2.64
120
986
15
70
2.21
2.02
2.6
1.5
0.0
0.0
g/l
0.49
15
64
21
113
1.93
1.98
2.8
2.0
1.7
1.5
g/l
0.37
16
95
9
33
2.79
1.95
1.2
1.2
—
—
—
0
0
14
65
2.22
1.91
2.7
1.4
0.0
0.0
g/l
0.00
14
59
16
79
2.09
1.89
3.8
1.4
1.8
0.3
g/l
0.80
16
68
228
2099
1.57
1.89
44.8
17.4
120.7
86.8
umol/l
7.46
228
2099
7
22
3.24
1.89
1.0
1.5
—
—
—
0
0
6
17
3.58
1.85
1.3
1.1
—
—
—
0
0
233
2159
1.59
1.84
49.2
21.5
123.7
135.3
g/l
20.47
227
2105
233
2159
1.59
1.84
49.0
21.4
4.2
4.5
e12/l
10.77
225
2063
18
95
1.96
1.80
2.3
1.5
—
—
—
0
0
6
18
3.38
1.75
1.3
1.1
—
—
—
0
0
6
18
3.38
1.75
1.3
1.1
—
—
—
0
0
6
18
3.38
1.75
1.3
1.1
—
—
—
0
0
6
18
3.38
1.75
1.3
1.1
—
—
—
0
0
6
18
3.38
1.75
1.3
1.1
—
—
—
0
0
18
96
1.94
1.75
3.0
2.6
342.0
846.9
ug/l
0.53
18
88
101
819
1.37
1.70
2.6
3.2
3022.3
1855.6
ng/l
0.60
92
708
16
85
1.94
1.58
2.5
1.4
11.4
10.7
g/l
0.34
16
71
10
44
2.32
1.55
1.1
1.3
—
—
—
0
0
96
784
1.35
1.52
7.4
4.3
—
—
—
0
0
5
16
3.16
1.44
1.8
1.6
—
—
—
0
0
22
136
1.67
1.37
4.6
2.7
1.0
1.1
%
0.02
22
136
6
23
2.64
1.37
1.3
1.3
—
—
—
0
0
9
42
2.18
1.35
1.1
1.3
—
—
—
0
0
5
18
2.81
1.29
4.8
1.7
—
—
—
0
0
5
18
2.81
1.29
1.2
1.2
110.4
53.0
u/l
—
5
13
6
25
2.43
1.25
1.3
1.6
—
—
—
0
0
223
2092
1.39
1.21
16.0
9.5
25.2
25.2
u/l
0.02
216
1977
85
711
1.29
1.10
1.9
2.2
219.2
359.8
u/l
0.56
80
657
19
287
0.64
1.09
1.2
1.3
3.9
13.4
u/ml
—
6
92
7
32
2.22
1.09
1.0
1.3
—
—
—
0
0
101
865
1.27
1.08
2.4
2.1
—
—
—
0
0
41
533
0.73
1.08
1.4
1.7
1.9
1.3
mmol/l
0.79
34
428
9
47
1.95
1.03
1.1
1.4
—
—
—
0
0
129
1155
1.22
0.89
4.7
4.2
2.3
2.1
ug/l
0.13
110
1016
10
56
1.82
0.89
1.1
1.2
—
—
—
0
0
64
533
1.26
0.85
1.9
1.8
991.8
1213.3
nmol/l
1.31
46
404
23
316
0.70
0.85
7.5
8.0
—
—
—
0
0
8
45
1.80
0.85
1.4
1.3
—
—
—
0
0
8
45
1.80
0.85
1.4
1.3
—
—
—
0
0
107
947
1.22
0.81
4.2
4.1
36.6
83.1
ng/l
0.78
88
737
76
649
1.24
0.81
1.7
1.6
18.9
20.6
nmol/l
0.45
67
538
6
34
1.78
0.77
1.2
1.2
—
—
—
0
0
5
24
2.10
0.75
1.2
1.3
—
—
—
0
0
5
25
2.02
0.73
1.6
1.3
17636.6
17526.9
e6/l
—
5
15
5
25
2.02
0.73
1.0
1.2
—
—
—
0
0
5
26
1.94
0.71
1.0
1.2
—
—
—
0
0
23
170
1.39
0.70
5.7
2.2
49.0
54.2
ml/min/173m2
0.46
12
66
5
28
1.80
0.66
1.2
1.2
—
—
—
0
0
191
1808
1.19
0.64
5.1
4.4
2.1
2.0
mu/l
0.12
173
1585
63
542
1.21
0.63
1.8
1.8
357.0
13043889.7
pmol/l
0.50
48
437
71
626
1.18
0.55
2.5
2.7
0.7
0.8
ug/l
0.60
50
443
48
408
1.21
0.55
1.4
1.8
2.8
1.4
mg/l
1.00
39
318
22
177
1.26
0.42
1.1
1.3
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
3.1
—
0
8
23
279
0.81
0.39
5.0
5.2
33.5
32.7
%
0.12
15
177
5
36
1.40
0.38
1.0
1.2
0.8
0.5
nmol/l
—
5
31
187
1936
0.89
0.36
4.6
5.0
1.3
1.4
mmol/l
1.19
171
1730
189
1955
0.89
0.36
4.7
5.0
4.1
4.3
mmol/l
2.02
170
1764
151
1442
1.11
0.33
3.8
3.4
15.1
15.1
pmol/l
0.09
134
1260
5
38
1.32
0.23
3.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
2.9
—
—
—
0
0
0
11
0.00
0.21
0.0
1.7
—
750.8
—
0
11
0
10
0.00
0.21
0.0
1.3
—
195.4
—
0
10
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
0.3
—
0
7
10
81
1.24
0.19
3.1
2.7
3.6
4.4
pmol/l
—
10
71
5
67
0.74
0.17
1.0
1.2
—
—
—
0
0
202
1984
1.07
0.16
5.3
5.2
6.2
6.2
mmol/l
0.00
180
1759
37
345
1.08
0.13
1.2
1.2
0.9
1.9
u/ml
—
10
96
199
2013
0.96
0.09
5.2
5.7
2.3
2.5
mmol/l
2.59
180
1802
52
499
1.05
0.09
7.7
4.4
1.0
1.0
kg/l
0.20
11
80
6
56
1.07
0.08
1.0
1.2
—
—
—
0
0
6
71
0.84
0.07
1.7
1.7
—
—
—
0
0
13
119
1.10
0.06
1.2
1.4
—
—
—
0
0
95
933
1.03
0.05
3.5
4.1
19.5
24.4
%
3.21
48
479
193
1940
0.98
0.02
7.2
6.9
41.2
41.3
mmol/mol
0.07
172
1757
188
1870
1.02
0.02
4.2
4.5
1.3
1.2
mmol/l
0.51
166
1659
0
6
0.00
0.00
0.0
1.0
—
2139.2
—
0
6
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
9.9
—
0
8
7
69
1.01
0.00
1.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
0.5
—
0
7
0
7
0.00
0.00
0.0
2.3
—
1.3
—
0
7
5
56
0.89
0.00
1.0
1.2
—
—
—
0
0
6
61
0.98
0.00
1.2
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
3.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
63.2
—
0
5
Mortality – FinRegistry
↥This endpoint is excluded (different definition than used in FinnGen).
Relationships between endpoints
↥Index endpoint: C3_URETER_EXALLC – Malignant neoplasm of ureter, excluding all cancers (controls excluding all cancers)
GWS hits: 1
This endpoint is excluded (different definition than used in FinnGen).